Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice

被引:0
作者
Tao, Shao-Hong [1 ]
Lei, Yu-Qing [1 ]
Tan, Yi-Mei [1 ]
Yang, Yu-Bo [2 ]
Xie, Wei-Ning [3 ]
机构
[1] Guangzhou Univ Chinese Med, Affiliated Guangdong Hosp Integrated Tradit Chines, Foshan, Peoples R China
[2] Jinan Univ, Sch Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Prov Hosp Integrated Tradit Chinese & We, Dept Sci Res, Dept Lab, Foshan, Guangdong, Peoples R China
关键词
metabolic dysfunction-associated steatotic liver disease; Chinese herbal formula; traditional Chinese medicine; mechanisms; review; DE-NOVO LIPOGENESIS; REGULATORY FACTOR 9; NONALCOHOLIC STEATOHEPATITIS; INSULIN-RESISTANCE; HEPATIC STEATOSIS; OXIDATIVE STRESS; GUT MICROBIOTA; KUPFFER CELLS; INFLAMMATION; FIBROSIS;
D O I
10.3389/fmed.2024.1476419
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, continues to rise with rapid economic development and poses significant challenges to human health. No effective drugs are clinically approved. MASLD is regarded as a multifaceted pathological process encompassing aberrant lipid metabolism, insulin resistance, inflammation, gut microbiota imbalance, apoptosis, fibrosis, and cirrhosis. In recent decades, herbal medicines have gained increasing attention as potential therapeutic agents for the prevention and treatment of MASLD, due to their good tolerance, high efficacy, and low toxicity. In this review, we summarize the pathological mechanisms of MASLD; emphasis is placed on the anti-MASLD mechanisms of Chinese herbal formula (CHF), especially their effects on improving lipid metabolism, inflammation, intestinal flora, and fibrosis. Our goal is to better understand the pharmacological mechanisms of CHF to inform research on the development of new drugs for the treatment of MASLD.
引用
收藏
页数:16
相关论文
共 113 条
  • [1] The role of the gut microbiota in nonalcoholic fatty liver disease
    Abu-Shanab, Ahmed
    Quigley, Eamonn M. M.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2010, 7 (12) : 691 - 701
  • [2] Plasma Myeloperoxidase Levels Correlate with the Presence of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
    Alkhouri, Naim
    Li, Lin
    Hanouneh, Ibrahim
    Feldstein, Ariel
    Hazen, Stanley
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S181 - S181
  • [3] Innate Immunity and Inflammation in NAFLD/NASH
    Arrese, Marco
    Cabrera, Daniel
    Kalergis, Alexis M.
    Feldstein, Ariel E.
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (05) : 1294 - 1303
  • [4] Mitogen-activated protein kinases in innate immunity
    Arthur, J. Simon C.
    Ley, Steven C.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2013, 13 (09) : 679 - 692
  • [5] Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury
    Baeck, Christer
    Wehr, Alexander
    Karlmark, Karlin Raja
    Heymann, Felix
    Vucur, Mihael
    Gassler, Nikolaus
    Huss, Sebastian
    Klussmann, Sven
    Eulberg, Dirk
    Luedde, Tom
    Trautwein, Christian
    Tacke, Frank
    [J]. GUT, 2012, 61 (03) : 416 - 426
  • [6] Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease
    Bibbo, Stefano
    Ianiro, Gianluca
    Dore, Maria Pina
    Simonelli, Claudia
    Newton, Estelle E.
    Cammarota, Giovanni
    [J]. MEDIATORS OF INFLAMMATION, 2018, 2018
  • [7] Traditional Chinese medicine Lingguizhugan decoction ameliorate HFD-induced hepatic-lipid deposition in mice by inhibiting STING-mediated inflammation in macrophages
    Cao, Lin
    Xu, Erjin
    Zheng, Rendong
    Zhangchen, Zhili
    Zhong, Rongling
    Huang, Fei
    Ye, Juan
    Sun, Hongping
    Fan, Yaofu
    Xie, Shaofeng
    Chen, Yu
    Xu, Yijiao
    Cao, Jing
    Cao, Wen
    Liu, Chao
    [J]. CHINESE MEDICINE, 2022, 17 (01)
  • [8] Multi-Omics Integration Analysis Identifies Lipid Disorder of a Non-Alcoholic Fatty Liver Disease (NAFLD) Mouse Model Improved by Zexie-Baizhu Decoction
    Cao, Yuhan
    Shi, Jingying
    Song, Luyao
    Xu, Junjiu
    Lu, Henglei
    Sun, Jianhua
    Hou, Jinjun
    Chen, Jing
    Wu, Wanying
    Gong, Likun
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] Qing-Zhi-Tiao-Gan-Tang (QZTGT) prevents nonalcoholic steatohepatitis (NASH) by expression pattern correction
    Chu, Hang
    Zhang, Weitao
    Tan, Yan
    Diao, Zhipeng
    Li, Peng
    Wu, Yapeng
    Xie, Like
    Sun, Jianguo
    Yang, Ke
    Li, Pingping
    Xie, Cen
    Li, Ping
    Hua, Qian
    Xu, Xiaojun
    [J]. JOURNAL OF ETHNOPHARMACOLOGY, 2023, 317
  • [10] Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach
    Dai, Liang
    Xu, Jingjuan
    Liu, Baocheng
    Dang, Yanqi
    Wang, Ruirui
    Zhuang, Lijie
    Li, Dong
    Jiao, Lulu
    Wang, Jianying
    Zhang, Lei
    Zhong, Linda L. D.
    Zhou, Wenjun
    Ji, Guang
    [J]. FRONTIERS OF MEDICINE, 2022, 16 (05) : 745 - 759